The control of hyperphosphataemia in haemodialysis patients.
Patients with chronic uraemia develop various metabolic abnormalities, the most significant being the low production of vitamin D [1.25(OH)2D3] by the kidneys (1-3), hyperphosphataemia, and hypocalcaemia (4). These abnormalities, occurring usually in combination, are responsible for the pathogenesis of secondary hyperparathyroidism (HPT) (5-11). Prevention and treatment of secondary HPT can be achieved by means of administration of vitamin D and calcium. However, the above treatment is conditional on a low serum phosphorus concentration.
Nurse of Renal Unit, University Hospital of Ioannina, Greece.
L
L
Papayianni
K
K
Katopodis
J
J
Kosmanou
A
A
Banioti
A
A
Katsaraki
M
M
Palatzidou
F
F
Prokopiou
V
V
Betsiou
K C
KC
Siamopoulos
D000328:Adult; D000368:Aged; D000536:Aluminum Hydroxide / Q000008:administration & dosage*; D000863:Antacids / Q000008:administration & dosage*; D002908:Chronic Disease; D004334:Drug Administration Schedule; D016903:Drug Monitoring; D005247:Feeding Behavior; D005260:Female; D006801:Humans; D006962:Hyperparathyroidism, Secondary / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D008297:Male; D008875:Middle Aged; D010710:Phosphates / Q000097:blood; D006435:Renal Dialysis; D014511:Uremia / Q000150:complications*
D000863:Antacids; D010710:Phosphates; D000536:Aluminum Hydroxide